CSIMarket
 


Aclaris Therapeutics Inc   (ACRS)
Other Ticker:  
 

Cumulative Aclaris Therapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period

ACRS's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ACRS Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Growth 6.64 % 3.75 % 15.31 % 54.17 % 39.5 %
Y / Y Current Assets Growth 24.68 % 7.5 % 41.92 % 256.62 % 254.81 %
Working Capital Ratio for Trailing Twelve Months Period 12.3 11.8 11.64 11.21 10.28
Total Ranking # 292 # 457 # 492 # 540 # 441
Seq. Current Liabilities Growth 22.92 % -7.47 % -27.06 % 28.54 % 19.6 %
Seq. Current Assets Growth -1.07 % 35.87 % -6.9 % -0.36 % -14.71 %


Working Capital Ratio for Trailing Twelve Months Period Comment
On the trailing twelve months basis Aclaris Therapeutics Inc Current Assets average grew by 24.68 % in III. Quarter year on year, faster than Current Liabilities, this led to increase in in Aclaris Therapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period to 12.3, Working Capital Ratio for Trailing Twelve Months Period remained below Aclaris Therapeutics Inc average.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Aclaris Therapeutics Inc . While Working Capital Ratio for Trailing Twelve Months Period overall ranking has improved so far to 292, from total ranking in previous quarter at 457.

What is Working Capital Ratio?
More about ACRS
Working Capital Ratio ACRS in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 117
Sector # 181
S&P 500 # 292


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
12.05 7.08 3.6
(Sep 30 2022)   (Mar 31 2020)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Nextcure Inc   32.81 
Stoke Therapeutics Inc   32.10 
Eqrx Inc   31.83 
Immix Biopharma Inc.  31.60 
Rezolute Inc   30.44 
Nanoviricides inc   30.30 
Day One Biopharmaceuticals Inc   30.05 
Synaptogenix Inc   28.93 
Xortx Therapeutics Inc   28.78 
Nuvalent Inc   28.46 
Kezar Life Sciences Inc   28.23 
Diamedica Therapeutics Inc   28.02 
Edgewise Therapeutics inc.  26.97 
Merrimack Pharmaceuticals Inc  26.97 
Spruce Biosciences Inc   26.94 
Janux Therapeutics Inc   26.91 
Karuna Therapeutics Inc   26.74 
Pmv Pharmaceuticals Inc   26.51 
Immuneering Corp  26.41 
Gemini Therapeutics Inc   26.21 
Dice Therapeutics Inc   25.72 
Anaptysbio inc  25.17 
Olema Pharmaceuticals inc   24.94 
Cyteir Therapeutics Inc   24.67 
Cassava Sciences Inc   24.63 
Silverback Therapeutics Inc   24.38 
Kura Oncology Inc   23.87 
Imago Biosciences Inc   23.87 
Sensei Biotherapeutics Inc   23.62 
Astria Therapeutics inc   23.42 


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

GTVI's Profile

Stock Price

GTVI's Financials

Business Description

Fundamentals

Charts & Quotes

GTVI's News

Suppliers

GTVI's Competitors

Customers & Markets

Economic Indicators

GTVI's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071